Inactive

THE SUBMISSION OF PRICING, CAPABILITIES FOR PLANNING PURPOSES, AND OTHER MARKET INFORMATION IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI IN ACCORDANCE WITH (IAW) FAR 15.201(e). This is a SOURCES SO... THE SUBMISSION OF PRICING, CAPABILITIES FOR PLANNING PURPOSES, AND OTHER MARKET INFORMATION IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI IN ACCORDANCE WITH (IAW) FAR 15.201(e). This is a SOURCES SOUGHT ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this sources sought must be in writing. The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified Service- Disabled Veteran Owned Small Businesses and Veteran Owned Small Businesses interested and capable of providing the services described below. Documentation of technical expertise must be presented in sufficient detail for the Government to determine that your company possesses the necessary functional area expertise and experience to compete for this acquisition. The North American Classification System (NAICS) code for this acquisition is NAICS Code 325412 Pharmaceutical Preparation Manufacturing (1,250 Employees). **Responses to this notice shall include Sources Sought number 36C26222Q0267 in the subject line of the email. **The following shall be provided in the capabilities statement or in body of email: Company name Address Point of contact Phone, fax, and email DUNS number Type of Large or small business, e.g. Services Disabled Veteran Owned Small Business, Veteran-owned small business If you are the manufacturer, please list any authorized distributors to include contact information. If you are a small business and you are an authorized distributor/reseller for the items identified above or an equivalent solution, do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified? Must provide a capability statement that addresses the organizations qualifications and ability to perform as a contractor for the work described below. Are you the manufacturer, distributor, or an equivalent solution to the items being referenced below? Provide any relevant FSS, NAC, GSA Contract vehicles company holds if applicable. If you are an FSS GSA/NAC or NASA SEWP contract holder or other federal contract holder, are the items/solution you are providing information for available on your schedule/contract? Please review salient characteristics/statement of work (if applicable) and provide feedback or suggestions. If none, please reply as N/A. List any available product options to meet all needs. ************************************************************************************* The Department of Veterans Affairs (VA), VISN 22 Network Contracting Office, is seeking PyLarify PIFLUFOLASTAT F 18 INJECTION or equivalent that meets the following salient characteristics for the VA Long Beach Healthcare System: Salient Characteristics/Specification Brand Name: PYLARIFY® (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) Product Numbers: NDC Product Description Manufacturer Product Number Qty Requested 71258-022-00 PYLARIFY® (piflufolastat F 18) Injection PYL-C 150 Manufacturer: Lantheus Salient Characteristics Must be an intravenous injection that is a radioactive diagnostic agent. To be used along with positron emission tomography (PET) imaging for men with prostate cancer. - Must be designed for use in patients with suspected metastasis who are candidates for initial definitive therapy. - Must be designed for use in patients with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. - Must be designed for use to detect prostate-specific membrane antigen (PSMA) positive lesions when used with PET imaging (scans) and assess prostate cancer. - Must have radioactive diagnostic imaging agent used with PET/CT scans to find tumors in the prostate, lymph nodes, bones, and other organs, typically better than other types of imaging scans. - Must have radioactive diagnostic imaging agent must attach to prostate-specific membrane antigen (PSMA), a protein found on the surface of most more than 90% prostate cancer cells. By targeting PSMA, PYLARIFY® can give your doctor a clear image and additional information on the location and the extent of the cancer. - Must use a radioactive tracer called fluorine-18, or 18F, which helps create a clear and more detailed PET/CT scan image for the doctor. -Must be FDA approved for use in detection and monitoring of prostate cancer ************************************************************************************* The information identified above is intended to be descriptive, not restrictive and to indicate the quality of the supplies/services that will be satisfactory. It is the responsibility of the interested source to demonstrate to the government that the interested parties can provide the supplies/services that fulfill the required specifications. If you are interested and capable of providing the sought-out supplies, please provide the requested information as well as the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions: *** Submissions addressing Salient Characteristics should show clear, compelling, and convincing*** evidence that all equal to items" meet all required salient characteristics. Important Information: The Government is not obligated to, nor will it pay for or reimburse any costs associated with responding to this source sought synopsis request. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. The VA is mandated by Public Law 109-461 to consider a total set-aside for Service-Disabled Veteran Owned Small Business set aside. However, if response by Service-Disabled Veteran Owned Small Business firms proves inadequate, an alternate set-aside or full and open competition may be determined. No sub-contracting opportunity is anticipated. Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered in the System for Award Management (SAM) at www.sam.gov and complete Online Representations and Certifications Application (ORCA). Additionally, all Service- Disabled Veteran-Owned Businesses or Veteran Owned Small Businesses who respond to a solicitation on this project must be registered with the Department of Veterans Affairs Center for Veterans Enterprise VetBiz Registry located at http://vip.vetbiz.gov. All interested Offerors should submit complete information by e-mail to April.Graves@va.gov. Include Sources Sought number 36C26222Q0267 in the subject line of the email All information submissions shall be received no later than 1:00 pm Pacific Standard Time on January 12, 2022. After review of the responses to this announcement, the Government intends to proceed with the acquisition and a subsequent solicitation may be published. If a solicitation is issued it shall be announced at a later date, and all interested parties must respond to that solicitation announcement separately from the responses to this request for information. Responses to this notice shall not be considered as requests to be added to a prospective bidders list or to receive a copy of the solicitation.